Active, not recruiting
NCT03631043: Phase 1 - Personalized Vaccine in Treating Participants With Smoldering MM
Updated: Feb 10
Personalized Vaccine in Treating Patients With Smoldering Multiple Myeloma
This early phase I trial studies the side effects of personalized vaccine in treating participants with smoldering multiple myeloma. Vaccines made from a person's blood and bone marrow may help the body build an effective immune response to kill cancer cells.
Sponsor
ClinicalTrials.gov Identifier: NCT03631043
Official Title: A Personalized Vaccine for the Immune Prevention of Multiple Myeloma
First Posted : August 15, 2018
Click here for details on ClinicalTrials.gov
Procedure: Biopsy Specimen Radiography
Drug: Lenalidomide
Biological: Vaccine Therapy
- Texas: The University of Texas MD Anderson Cancer Center Houston
Location
United States, Texas